Why we'll need more than machines to demystify the microbiome

9 October 2019
david_evendon_challis-_rb_large

Collaboration will be crucial to keeping up with growing consumer demand for microbiome support, writes David Evendon-Challis, vice president of innovation at the consumer goods firm, RB (LON: RB), in an Expert View piece.

Around the world, attitudes to healthcare are changing. Long-gone are the days of occasional GP visits – more and more individuals are adopting increasingly sophisticated self-care solutions in an effort to take their health into their own hands.

Probiotic yogurts just the start

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology